Effects of a serotonin 5-HT4 receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans

• Published in: Gut Vol. 47; no. 5; pp. 667 - 674
• Main Authors: Bharucha, A E, Camilleri, M, Haydock, S, Ferber, I, Burton, D, Cooper, S, Tompson, D, Fitzpatrick, K, Higgins, R, Zinsmeister, A R
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and British Society of Gastroenterology 01.11.2000; BMJ; BMJ Publishing Group LTD
• Subjects: 5-HT4 receptors; Biological and medical sciences; Colon; colon transit; Digestive system; gastrointestinal motor function; gastrointestinal sensory function; Irritable bowel syndrome; Laboratories; Medical sciences; Pharmaceuticals; Pharmacology. Drug treatments; Rodents; Serotonin; Smooth muscle; Studies; Human; Stomach; 5-HT4 Serotonine receptor; Neuroendocrinology; Healthy subject; Digestive system; Gut; Experimental study; Gastrointestinal; Biological activity; Digestive transit; Regulation(control); Sensitivity; Antagonist; Motricity
• ISSN: 0017-5749; 1468-3288; 1458-3288
• DOI: 10.1136/gut.47.5.667

BACKGROUND Serotonin 5-HT4 receptors are located on enteric cholinergic neurones and may regulate peristalsis. 5-HT4 receptors on primary afferent neurones have been postulated to modulate visceral sensation. While 5-HT4 agonists are used as prokinetic agents, the physiological role of 5-HT4 receptors in the human gut is unknown. AIMS Our aim was to characterise the role of 5-HT4 receptors in regulating gastrointestinal motor and sensory function in healthy subjects under baseline and stimulated conditions with a 5-HT4 receptor antagonist. METHODS Part A compared the effects of placebo to four doses of a 5-HT4receptor antagonist (SB-207266) on the cisapride mediated increase in plasma aldosterone (a 5-HT4 mediated response) and orocaecal transit in 18 subjects. In part B, 52 healthy subjects received placebo, or 0.05, 0.5, or 5 mg of SB-207266 for 10–12 days; gastric, small bowel, and colonic transit were measured by scintigraphy on days 7–9, and fasting and postprandial colonic motor function, compliance, and sensation during distensions were assessed on day 12. RESULTS Part A: 0.5, 5, and 20 mg doses of SB-207266 had significant and quantitatively similar effects, antagonising the cisapride mediated increase in plasma aldosterone and acceleration of orocaecal transit. Part B: SB-207266 tended to delay colonic transit (geometric centre of isotope at 24 (p=0.06) and 48 hours (p=0.08)), but did not have dose related effects on transit, fasting or postprandial colonic motor activity, compliance, or sensation. CONCLUSION 5-HT4receptors are involved in the regulation of cisapride stimulated orocaecal transit; SB 207266 tends to modulate colonic transit but not sensory functions or compliance in healthy human subjects.